Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | CDC25A | P30304 | 4/20 | 0.32 |
| ▸ | CDC25B | P30305 | 4/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5590042 | 0.88 | PTPN1 (0.41) | PTPN1CDC25ACDC25BCA12CA1 | |
| SCHEMBL5590269 | 0.86 | CDC25B (0.37) | PTPN1CDC25ACDC25B | |
| SCHEMBL5589729 | 0.71 | PDE2A (0.33) | PTPN1CA12CA1CA2CA7 | |
| SCHEMBL17532553 | 0.71 | PTPRC (0.37) | CDC25B | |
| SCHEMBL5587476 | 0.70 | CA12 (0.39) | PTPN1CA12CA1CA2CA7 | |
| SCHEMBL9641989 | 0.70 | CDC25B (0.52) | PTPN1CDC25ACDC25BCA12CA1 | |
| SCHEMBL5589809 | 0.69 | CDC25A (0.44) | PTPN1CDC25ACDC25BKMT2AMEN1 | |
| SCHEMBL13417406 | 0.68 | MCOLN3 (0.36) | PTPN1CA12CA1CA2CA7 | |
| SCHEMBL9627555 | 0.65 | CDC25B (0.57) | PTPN1CDC25ACDC25BKMT2AMEN1 | |
| SCHEMBL29208407 | 0.65 | CYP2A6 (0.37) | PTPN1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | PTPN1 4679/4885CDC25A 1871/4885CDC25B 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.